{"id":"acetylsalicylic-morning","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Gastrointestinal bleeding or ulceration"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":"2-5","effect":"Nausea"},{"rate":null,"effect":"Increased bleeding risk"},{"rate":"0.5-1","effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL2429949","moleculeType":"Small molecule","molecularWeight":"308.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acetylsalicylic acid (aspirin) acetylates serine residues on COX-1 and COX-2 enzymes, permanently blocking their catalytic activity. This reduces synthesis of prostaglandins (involved in inflammation and pain) and thromboxane A2 (a platelet aggregator), resulting in anti-inflammatory, pain-relieving, and blood-thinning effects. The antiplatelet effect is particularly durable because it affects long-lived platelets that cannot synthesize new COX-1.","oneSentence":"Acetylsalicylic acid irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to provide anti-inflammatory, analgesic, and antiplatelet effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:52.568Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cardiovascular disease prevention (secondary prevention post-myocardial infarction or stroke)"},{"name":"Acute coronary syndrome"},{"name":"Pain and fever management"},{"name":"Inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT05761015","phase":"PHASE4","title":"Helping Osteoarthritis Patients to Walk With NSAID","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2023-12-14","conditions":"Osteoarthritis, Knee, Osteoarthritis, Hip, Chronic Pain","enrollment":55},{"nctId":"NCT07361679","phase":"PHASE4","title":"LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention","status":"RECRUITING","sponsor":"Alexandra Hospital, Athens, Greece","startDate":"2023-01-18","conditions":"Preeclampsia Severe, Toxemia Of Pregnancy, Preeclampsia","enrollment":100},{"nctId":"NCT02685748","phase":"PHASE2, PHASE3","title":"Aspirin in Young Psychotic Patients","status":"COMPLETED","sponsor":"Clinic for Psychiatric Disorders, Dr Laza Lazarevic","startDate":"2017-07-20","conditions":"Psychosis, Acute Psychosis, Schizophrenia","enrollment":60},{"nctId":"NCT04132791","phase":"NA","title":"TIME ASPIRIN: Chronotherapy With Aspirin for Reduction of Cardiovascular Disease","status":"TERMINATED","sponsor":"Leiden University Medical Center","startDate":"2019-10-07","conditions":"Cardiovascular Diseases","enrollment":328},{"nctId":"NCT03011775","phase":"PHASE4","title":"Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease","status":"COMPLETED","sponsor":"Ukrainian Medical Stomatological Academy","startDate":"2012-11","conditions":"Adverse Effect, Atherosclerosis, Coronary, Insulin Resistance Syndrome","enrollment":43},{"nctId":"NCT01797575","phase":"PHASE2","title":"N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2013-01","conditions":"Bipolar Disorder","enrollment":38},{"nctId":"NCT03206944","phase":"PHASE4","title":"Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects","status":"COMPLETED","sponsor":"Beata Krasinska","startDate":"2015-07-01","conditions":"Hypertension,Essential, Obesity","enrollment":82},{"nctId":"NCT00748371","phase":"PHASE4","title":"Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration","status":"TERMINATED","sponsor":"Vanderbilt University","startDate":"2004-06","conditions":"Platelet Aggregation","enrollment":51},{"nctId":"NCT01741922","phase":"PHASE3","title":"Effectiveness of Night Administration of Low Dose Aspirin in Hypertensive Patients","status":"COMPLETED","sponsor":"Basque Health Service","startDate":"2012-12","conditions":"Hypertension","enrollment":230},{"nctId":"NCT02090413","phase":"PHASE4","title":"Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-05","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":241},{"nctId":"NCT01568112","phase":"PHASE3","title":"Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate","status":"COMPLETED","sponsor":"Biogen","startDate":"2012-04","conditions":"Healthy","enrollment":173},{"nctId":"NCT00467584","phase":"PHASE3","title":"Aspirin for Treatment of Multiple Sclerosis-Related Fatigue","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2007-07","conditions":"Multiple Sclerosis, Fatigue","enrollment":62},{"nctId":"NCT01227629","phase":"PHASE2","title":"PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-09","conditions":"Atrial Fibrillation","enrollment":502},{"nctId":"NCT01506505","phase":"NA","title":"The Evening Versus Morning Polypill Utilization Study","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2012-07","conditions":"Cardiovascular Disease, Cerebrovascular Disease, Peripheral Arterial Disease","enrollment":78}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":51,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Asa","Low dose","aspirine"],"phase":"phase_3","status":"active","brandName":"Acetylsalicylic morning","genericName":"Acetylsalicylic morning","companyName":"Basque Health Service","companyId":"basque-health-service","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acetylsalicylic acid irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to provide anti-inflammatory, analgesic, and antiplatelet effects. Used for Cardiovascular disease prevention (secondary prevention post-myocardial infarction or stroke), Acute coronary syndrome, Pain and fever management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}